Authors: Moazeni-Roodi, Abdolkarim
Hashemi, Mohammad
Title: Association between miR-124-1 rs531564 polymorphism and risk of cancer
Other Titles: an updated meta-analysis of case-control studies
Language (ISO): en
Abstract: Many studies examined the association between miR-124-1 rs531564 polymorphism and the risk of some human cancers, but the findings remain controversial. This update meta-analysis aimed to validate the association between rs531564 polymorphism of miR-124-1 and cancer risk. Eligible studies including 6,502 cancer cases and 7,213 controls were documented by searching Web of Science, PubMed, Scopus, and Google scholar databases. Pooled odds ratios (ORs) with 95 % confidence intervals (CIs) were estimated to quantitatively evaluate the association between rs531564 variant and cancer risk. The results indicated that rs531564 variant significantly decreased the risk of cancer in homozygous codominant (OR=0.54, 95 % CI=0.43-0.69, p<0.00001, GG vs CC), dominant (OR=0.84, 95 % CI=0.72-0.99, p=0.03, CG+GG vs CC), recessive (OR=0.65, 95 % CI=0.54-0.78, p<0.00001, GG vs CG+CC), and allele (OR=0.84, 95 % CI=0.73-0.96, p=0.008, G vs C) genetic model. Stratified analysis by cancer type revealed that rs531564 variant was associated with gastric cancer, cervical cancer, esophageal squamous cell carcinoma and colorectal cancer risk. In summary, the findings of this meta-analysis support an association between miR-124-1 rs531564 polymorphism and cancer risk. Larger and well-designed studies are required to estimate this association in detail.
Subject Headings: miR-124-1
rs531564
Polymorphism
Cancer
Meta-analysis
URI: http://hdl.handle.net/2003/37649
http://dx.doi.org/10.17877/DE290R-19644
Issue Date: 2018-06-28
Rights link: https://creativecommons.org/licenses/by/4.0/
Appears in Collections:Original Articles

Files in This Item:
File Description SizeFormat 
Hashemi_28062018_proof.pdfDNB1.6 MBAdobe PDFView/Open


This item is protected by original copyright



All resources in the repository are protected by copyright.